肝细胞癌经动脉化疗栓塞前后的弥散加权成像:在生存预测与疗效评估中的作用
该回顾性分析纳入2008至2017年在一家三级转诊中心接受TACE治疗的89例HCC患者,于首次TACE前后≤3个月内用DWI测量肿瘤及肝实质ADC值。TACE后肿瘤ADC由1081 mm²/s升至1328 mm²/s(p<0.001),mRECIST应答者ΔADC高于非应答者(26% vs 14%,p=0.048);TACE前ADC与ΔADC均与OS无显著关联,mRECIST应答为OS的独立预测因素。
要点
- TACE后肿瘤ADC由1081 mm²/s升至1328 mm²/s(p<0.001),ADC升高可反映治疗反应。
- mRECIST应答者ΔADC为26%,非应答者为14%(p=0.048),应答者ADC升高更明显。
- TACE前ADC与ΔADC均非OS的独立预测因素,mRECIST应答为OS独立预测因素。
核心结论
- mRECIST被证实为OS的独立预后因素,而TACE前或TACE后ADC测量均非OS的独立预后因素;mRECIST应答与ADC升高幅度大于非应答相关。
研究设计与样本
- 回顾性分析,纳入2008至2017年在一家三级转诊中心接受TACE治疗的89例HCC患者,于首次TACE前后≤3个月内行DWI测量HCC病灶(≥1 cm)及肝实质的ADC值。
关键影像表现/征象
- TACE后肿瘤ADC由1081 mm²/s(IQR 964-1225)升至1328 mm²/s(IQR 1197-1560),p<0.001。
- mRECIST应答者首次TACE后ΔADC为26%,非应答者为14%(p=0.048)。
诊断标准与关键数值
- 肿瘤疗效按mRECIST评估,分为应答者与非应答者。
- TACE前ADC与ΔADC在单变量和多变量Cox回归分析中均与OS无显著关联。
- mRECIST应答在Cox回归分析中为OS的独立预测因素。
临床应用与阅片要点
- 原文结论为mRECIST应答是OS的独立预测因素,TACE前或TACE后ADC测量不是。
- 原文报告mRECIST应答者ΔADC高于非应答者(26% vs 14%,p=0.048)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Survival outcomes of patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) are heterogeneous. Measuring the apparent diffusion coefficient (ADC) using diffusion-weighted imaging (DWI) may improve overall survival prediction.
AIM: To assess the value of measuring the ADC before and after TACE in predicting overall survival.
METHODS: A retrospective analysis was performed in HCC patients treated with TACE at a tertiary referral center between 2008 and 2017. The ADC values and changes in ADC value (ΔADC) of HCC lesions (≥ 1 cm) and liver parenchyma were assessed by DWI ≤ 3 months before and after first TACE. Pre- and post-TACE ADC values were compared with tumor response according to mRECIST and correlated with overall survival (OS) in a univariable and multivariable Cox-regression analysis.
RESULTS: A total of 89 patients were included, mostly Child-Pugh A (85%) and BCLC stage B (53%) with a median OS of 21.7 months (95% CI 17.6-25.9). Tumor ADC increased from 1081 mm2/s before (IQR 964-1225) to 1328 mm2/s (IQR 1197-1560) after TACE (p < 0.001). Responders according to mRECIST showed a higher ΔADC after first TACE than non-responders (26 vs. 14%, p = 0.048). Pre-TACE ADC and ΔADC were not significantly associated with OS in both univariable and multivariable analysis, whereas response according to mRECIST remained an independent predictor of OS.
CONCLUSION: mRECIST was confirmed as an independent prognostic factor of OS, but pre- or post-TACE ADC measurements were not. Response according to mRECIST was associated with a higher increase in ADC than non-response.
引用
- Labeur TA, Runge JH, Klompenhouwer EG, et al. Diffusion-weighted imaging of hepatocellular carcinoma before and after transarterial chemoembolization: role in survival prediction and response evaluation. Abdom Radiol (NY). 2019. PMID: 31069479. doi:10.1007/s00261-019-02030-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。